La cadena de opciones muestra datos clave de las opciones de acciones de Xilio Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Xilio Therapeutics..

Xilio Therapeutics (NASDAQ:XLO) Bolsa, Cadena de Opciones

Xilio Therapeutics

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

AADI

APTO

CADL

CARA

HUMA

MESO

MOBX

MTEM

NVNI

OCEA

PRFX

QUBT

ZCAR

FedEx sube un 8,7% con resultados sólidos y una nueva estrategia. Descubre otras acciones destacadas en premercado hoy.

Las acciones de FedEx (FDX) suben alrededor de un 9%; 20 acciones que se mueven en premercado

Xilio Therapeutics Inc

Texas Instruments's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NYSE">TXN</a>) short percent of float has fallen 12.71% since its last report. The company recently reported that it has 16.83 million shares sold short, which is 2.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Texas Instruments Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751385626_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Texas Instruments has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Texas Instruments's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Texas Instruments's peer group average for short interest as a percentage of float is 5.30%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Texas Instruments's Recent Short Interest

SolarEdge Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NYSE">SEDG</a>) short percent of float has fallen 12.33% since its last report. The company recently reported that it has 15.92 million shares sold short, which is 31.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.65 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>SolarEdge Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751385621_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SolarEdge Technologies has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing SolarEdge Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, SolarEdge Technologies's peer group average for short interest as a percentage of float is 7.71%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SEDG

How Do Investors Really Feel About SolarEdge Technologies?

Blue Owl Capital's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) short percent of float has risen 28.81% since its last report. The company recently reported that it has 37.75 million shares sold short, which is 6.93% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.46 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Blue Owl Capital Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751385615_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Blue Owl Capital has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Blue Owl Capital's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Blue Owl Capital's peer group average for short interest as a percentage of float is 3.50%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About Blue Owl Capital?

Susquehanna analyst Charles Minervino maintains Oil States International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIS#NYSE">OIS</a>) with a Neutral and raises the price target from $4.5 to $5.5.

News

Price Target

Analyst Ratings

Susquehanna Maintains Neutral on Oil States International, Raises Price Target to $5.5

JP Morgan analyst Destiny Jackson initiates coverage on Omada Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMDA#NASDAQ">OMDA</a>) with a Overweight rating and announces Price Target of $20.

Initiation

OMDA

JP Morgan Initiates Coverage On Omada Health with Overweight Rating, Announces Price Target of $20

<a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1082425" title="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1082425">https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1082425</a>

Biotech

General

MBIO

Mustang Bio Receives FDA Orphan Drug Designation For MB-101 Treatment Of Malignant Glioma

Mustang Bio Designated Orphan Designation Status For "an autologous ex vivo expanded cluster of differentiation 62-enriched naive and memory T-cell investigational product that has been genetically modified using a self-inactivating lentiviral vector to express an IL13Ralpha2-targeted, hinge-optimized, 4-1BB-costimulatory chimeric antigen receptor with a truncated CD19" For The Treatment Of Malignant Glioma

WIIM

HUBG

Hub Group shares are trading higher after Baird reinstated an Outperform rating on the stock and announced a price target of $44.

Susquehanna analyst Charles Minervino maintains NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) with a Positive and lowers the price target from $19 to $18.

Susquehanna Maintains Positive on NOV, Lowers Price Target to $18

Susquehanna analyst Charles Minervino maintains Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) with a Neutral and raises the price target from $25 to $30.

Susquehanna Maintains Neutral on Noble Corp, Raises Price Target to $30

Olin shares are trading higher after the company announced an expansion of its partnership with K2 Pure Solutions.

Susquehanna analyst Charles Minervino maintains Nabors Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBR#NYSE">NBR</a>) with a Neutral and raises the price target from $29 to $32.

Susquehanna Maintains Neutral on Nabors Industries, Raises Price Target to $32

Susquehanna analyst Charles Minervino maintains Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) with a Positive and lowers the price target from $24 to $23.

Susquehanna Maintains Positive on Helmerich & Payne, Lowers Price Target to $23

YAAS

Youxin Technology Shares Resume Trade

Susquehanna analyst Charles Minervino maintains TechnipFMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) with a Positive and raises the price target from $35 to $40.

Susquehanna Maintains Positive on TechnipFMC, Raises Price Target to $40

The first half of 2025 has come to a close and 21 of the 30 stocks that make up the <a href="https://www.benzinga.com/topic/dow-jones-industrial-average">Dow Jones Industrial Average Index</a> are positive year-to-date.
Despite the impressive number of stocks with a positive performance in the first six months, the index was up around 4% with several of the components posting large declines.
2025 Performance: Through the first six months of the year, two <a href="https://www.benzinga.com/topic/magnificent-seven">Magnificent Seven stocks </a>are among the 10 best in the Dow Jones Industrial Average and two are among the 10 worst in the index based on performance.
Here's a look at the 10 best Dow Jones Industrial Average stocks in the first half:
<ol class="wp-block-list">
<li>International Business Machines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>): +34.1%</li>
<li>Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>): +23.6%</li>
<li>JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>): +20.9%</li>
<li>Boeing Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): +18.4%</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>): +18.0%</li>
<li>3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>): +17.9%</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>): +17.6%</li>
<li>Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>): +17.2%</li>
<li>Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): +13.6%</li>
<li>Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>): +12.3%</li>
</ol>
Here are the 10 worst performing Dow Jones Industrial Average stocks in the first half:
<ol class="wp-block-list">
<li>UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>): -38.3%</li>
<li>Merck &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): -20.4%</li>
<li>Salesforce.com Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>): -18.4</li>
<li>Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>): -18.1%</li>
<li>Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>): -6.1%</li>
<li>Home Depot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>): -5.7%</li>
<li>Procter &amp; Gamble Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>): -5.0%</li>
<li>Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>): -1.1%</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): Flat</li>
<li>McDonald's Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NASDAQ">MCD</a>): +0.8%</li>
</ol>
Overall the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), which tracks the index, was up around 4% in the first half of 2025. This was a lower gain than the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, which had a 5.7% gain in the first half.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45932660/exclusive-sp-500-new-all-time-highs-again-2025">EXCLUSIVE: S&amp;P 500 To Hit New All-Time Highs Again In 2025? Majority Say Yes, 27% Predict This Range</a>
Why It's Important: Nvidia was one of the new Dow Jones components <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/12/42726598/dow-jones-2024-scoreboard-top-5-winners-losers-and-how-amazon-nvidia-could-reshape-2025">added in 2024</a> and the stock is one of the top performers in the first half of 2025. The stock replaced Intel, which was a top decliner in recent years.
The index also got rid of Walgreens, which was another poor performer in recent years. Its replacement Amazon was flat for the first half of 2025.
The new index makeup is showing strong signs of positive returns.
With 21 of the components positive year-to-date and one flat, this could mark one of the best years by the number of gainers in recent history.
In 2024, 18 of the 30 stocks were up for the full year. In 2023, 19 of the stocks in the index were up.
Perhaps most surprising is that two of the Magnificent Seven stocks rank among the worst performers in the first half of 2025, despite being part of the four Mag 7 members included in the Dow Jones Industrial Average.
Apple was the fourth-worst performer in the index for the first half, falling 18.1%. That marks a sharp reversal from its standout status as the only Dow Jones stock to rank among the top gainers in both 2023 and 2024.
Amazon ranked ninth with a flat return, as only eight of the components were down. 
The Dow Jones Industrial Average remains one of the most closely watched stock market indexes, serving as a gauge of overall market health. With only 30 stocks and a weighting based on stock price, rather than market capitalization, the index is less frequently used by some analysts and market experts than the broader S&amp;P 500 Index.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46198021/nvidia-vs-microsoft-vs-apple-which-stock-reaches-4-trillion-first">Nvidia Vs. Microsoft Vs. Apple: Which Stock Reaches $4 Trillion First?</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Large Cap

Education

AAPL

AMZN

CSCO

SPDR Dow Jones Industrial Average ETF Trust

MSFT

NVDA

Dow Jones 2025 First Half Scoreboard: Top 10 Winners, Losers — Where Do Nvidia, Apple Stock Rank?

GRAN

Trading Halt: Halt status updated at 11:50:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Youxin Technology Shares Halted On Circuit Breaker To The Downside, Stock Now Down -83.2%

Jefferies analyst Christopher LeFemina initiates coverage on Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) with a Hold rating and announces Price Target of $110.

Jefferies Initiates Coverage On Alpha Metallurgical with Hold Rating, Announces Price Target of $110

<a href="https://www.cnn.com/politics/live-news/trump-big-beautiful-bill-vote-07-01-25">https://www.cnn.com/politics/live-news/trump-big-beautiful-bill-vote-07-01-25</a>

ARRY

CSIQ

FSLR

SHLS

SPWR

TSLA

'Republicans Relax Some Restrictions On Wind And Solar Projects'- CNN

Press Releases

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

Markets

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Earnings

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

Health Care

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

IPOs

Xilio Therapeutics Announces Proposed Public Offering

Financing

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Management

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

ABVC BioPharma

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Clene

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

MiNK Therapeutics

Kala Bio

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Kezar Life Sciences

Lantern Pharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PepGen

Pluri

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Rein Therapeutics

Shattuck Labs

vTv Therapeutics Inc. - Class A Common Stock

Comments

Xilio Therapeutics

Xilio Therapeutics (XLO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL